Evidence map›Paper›PMID 30275242›Full record

ArticleMolecular cancer therapeutics2018

Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer.

Yu Sunakawa, Kaoru Mogushi, Heinz-Josef Lenz, Wu Zhang, Akihito Tsuji, Takehiro Takahashi, Tadamichi Denda, Ken Shimada, Mitsugu Kochi, Masato Nakamura and 10 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 15 institutions in 2 countries.

Yu Sunakawa *Department of Clinical Oncology, St. Marianna University School of Medicine, Miyamae-ku, Kawasaki, Kanagawa, Japan. y.suna0825@gmail.com.ORCID 0000-0002-0163-7543
Kaoru Mogushi *Diagnostics and Therapeutics of Intractable Diseases, Intractable Disease Research Center, Juntendo University Graduate School, Tokyo, Japan.
Heinz-Josef LenzDivision of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
Wu ZhangDivision of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
Akihito TsujiDepartment of Clinical Oncology, Kagawa University Faculty of Medicine Cancer Center, Kagawa University Hospital, Kita, Kagawa, Japan.
Takehiro TakahashiDivision of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan.
Tadamichi DendaDivision of Gastroenterology, Chiba Cancer Center, Chuo, Chiba, Japan.
Ken ShimadaDivision of Medical Oncology, Department of Internal Medicine, Showa University Koto Toyosu Hospital, Koto, Tokyo, Japan.
Mitsugu KochiDepartment of Digestive Surgery, Nihon University School of Medicine, Itabashi, Tokyo, Japan.ORCID 0000-0003-2781-4947
Masato NakamuraAizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Nagano, Japan.
Masahito KotakaGastrointestinal Cancer Center, Sano Hospital, Kobe, Hyogo, Japan.
Yoshihiko SegawaDepartment of Medical Oncology, International Medical Center, Saitama Medical University, Saitama, Hidaka, Japan.
Hiroaki TaniokaDepartment of Clinical Oncology, Kawasaki Medical School, Kurashiki City, Okayama, Japan.
Yuji NegoroDepartment of Gastroenterology, Kochi Health Sciences Center, Kochi, Japan.
Miriana MoranR&D and Pharmaceutical Services, Cancer Genetics, Inc., Los Angeles, California.
Stephanie H AstrowKite, a Gilead Company, Santa Monica, California.
Jack HsiangR&D and Pharmaceutical Services, Cancer Genetics, Inc., Los Angeles, California.
Craig StephensR&D and Pharmaceutical Services, Cancer Genetics, Inc., Los Angeles, California.
Masashi FujiiDepartment of Digestive Surgery, Nihon University School of Medicine, Itabashi, Tokyo, Japan.
Wataru IchikawaDivision of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan.ORCID 0000-0001-5543-4488
Cancer Genetics (United States) · USNihon University · JPShowa University Fujigaoka Hospital · JPUSC Norris Comprehensive Cancer Center · USAadi (United States) · USAizawa Hospital · JPChiba Cancer Center · JPCHI Health · USHyogo Prefectural Cancer Center · JPJuntendo University · JPKagawa University Hospital · JPKawasaki Medical School · JPKoto Hospital · JPSaitama International Medical Center · JPSt. Marianna University School of Medicine · JP

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

Molecular differences in tumor locations may contribute to the sidedness-specific response to cetuximab in metastatic colorectal cancer (mCRC). We investigated genes associated with the response to cetuximab treatment depending on tumor sidedness. Our study included 77 patients with mCRC (13/63, right/left) with

Indexed as

Genes, NeoplasmCell Line, TumorCetuximabColorectal NeoplasmsDisease-Free SurvivalGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateNeoplasm MetastasisPrognosisReceptor, Notch1CetuximabNOTCH1 protein, humanReceptor, Notch1

Identifiers

PMID30275242
PMCPMC7497846
OpenAlexW2894832031

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.